This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use
by Zacks Equity Research
AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.
Bayer to Invest 5 Billion Euros in Weedkiller Research
by Zacks Equity Research
Bayer (BAYRY) announces that it will invest 5 billion euros in developing new weedkillers amid lawsuits claiming its glyphosate-based weedkillers cause cancer.
J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study
by Zacks Equity Research
J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.
Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz
by Zacks Equity Research
Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.
Agilent Announces Receipt of FDA Approval for pharmDX Assay
by Zacks Equity Research
Agilent (A) receives approval on the expanded use of its PD-L1 IHC 22C3 pharmDx assay.
3 Big Pharma Stocks to Buy Right Now
by Zachary Stutler
These big pharma stocks all have a Zacks Rank #2 or better.
Dow 30 Stock Roundup: United Technologies-Raytheon Merger, Merck's Tilos Buyout
by Swarup Gupta
The index traversed a volatile week, guided largely by trade-related developments.
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
by Kinjel Shah
Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.
Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230
by Zacks Equity Research
Alkermes (ALKS) initiates monotherapy expansion phase of ALKS 4230 to treat patients with renal cell carcinoma or melanoma.
Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock
by Zacks Equity Research
Here are five reasons why investors may consider betting on Merck (MRK) stock
Novartis Reports Data on Cosentyx for Psoriatic Arthritis
by Zacks Equity Research
Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Boost Your Portfolio's Health With These 3 Big Drug Stocks
by Kinjel Shah
The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.
Lilly Announces Tradjenta Cardiovascular Outcome Study Data
by Zacks Equity Research
Tradjenta leads to fewer events of hypoglycemia and modest weight reduction in type II diabetes patients compared to Sanofi's Amaryl.
Merck (MRK) to Buy Private Biotech Tilos for Up to $773M
by Zacks Equity Research
Merck (MRK) set to buy private preclinical biotech Tilos Therapeutics in a deal that could be worth up to $773 million
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $82.48, marking a +0.02% move from the previous day.
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca
The Zacks Analyst Blog Highlights: Microsoft, Cisco, Merck and Chevron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Cisco, Merck and Chevron
AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study
by Zacks Equity Research
AstraZeneca's (AZN) lymphoma drug, Calquence, meets the primary endpoint and a key secondary one in a phase III study for the first-line treatment of chronic lymphocytic leukaemia.
Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache
by Kinjel Shah
Pharma bigwigs present data from cancer studies at ASCO. Lilly's (LLY) CGRP Emgality gets FDA approval for episodic cluster headache in adults.
Dow 30 Stock Roundup: UNH to Hike Dividend, MRK Zerbaxa's New Indication Gets FDA Nod
by Swarup Gupta
The index enjoyed a week of strong gains after the Fed Chair indicated that a near-term rate cut was increasingly likely.
5 Top Dow Stock Gainers of Past Month Still Holding Momentum
by Nalak Das
Despite severe market volatility, the blue-chip index of Wall Street has provided double-digit returns to investors so far this year.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Was ASCO Quieter for Big Drug/Biotech Stocks This Year?
by Kinjel Shah
The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.
Cancer-Fighting Stocks & ETF: What You Need to Know
by Neena Mishra
Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference